SUBSCRIBE
SUBSCRIBE
News   Drug Development

AstraZeneca PLC’s Recentin Flunks Colon Cancer Tests

May 28, 2010 | 
1 min read
LONDON, May 28 (Reuters) - AstraZeneca (AZN.L) dropped plans to file experimental cancer drug Recentin as a first-line treatment for colon cancer on Friday after disappointing results from a second pivotal clinical trial with the medicine.
Clinical research Phase 2
AstraZeneca
MORE ON THIS TOPIC
Digital overload and its impact on the human brain, showcasing fragmented thoughts, information overload. Abstract design art collage. Social media digital addiction, mental health, stress, anxiety
Neuropsychiatric disorders
Otsuka’s drug eases symptom burden, anxiety in ADHD as FDA verdict nears
June 26, 2026
 · 
2 min read
 · 
Tristan Manalac
Businessmen look at the city from the outskirts.
Pipeline
Moderna looks out to R&D ‘horizons’ as 2028 break-even goal looms
June 26, 2026
 · 
2 min read
 · 
Tristan Manalac
Plan to buying new house or renovation, mortgage loan or housing expense, property maintenance or real estate insurance concept, smart businessman put jigsaw to complete or finishing house puzzle.
FDA
BIO 2026: FDA’s IND initiative is a step toward normalization after slipshod year
June 25, 2026
 · 
3 min read
 · 
Jef Akst
Insights
The Golden Triangle and the gaps: Rethinking UK biotech
June 25, 2026
 · 
1 min read
 · 
Jennifer C. Smith-Parker